Feedback

Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review

Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Song, Yuanbin;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Chen, Shuzhao;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Liu, Chenfei;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Chen, Lezong;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Wang, Weida;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Wu, Bingyi;
Affiliation
Department of Hematologic Oncology ,State Key Laboratory of Oncology in South China ,Collaborative Innovation Center for Cancer Medicine ,Sun Yat-sen University Cancer Center ,Guangzhou ,China
Liang, Yang

Maintenance therapy in adult T-cell acute lymphoblastic leukemia (T-ALL) is the longest phase but with limited option. The classic drugs used in the maintenance phase such as 6-mercaptopurine, methotrexate, corticosteroid and vincristine have potentially serious toxicities. Optimizing therapy in the modern age, chemo-free maintenance therapy regimens for patients with T-ALL may dramatically improve the maintenance therapeutic landscape. We report here the combination of Anti-programmed cell death protein 1 antibody and histone deacetylase inhibitor as chemo-free maintenance treatment in a T-ALL patient with literature review, thus providing a unique perspective in addition to valuable information which may inform novel therapeutic approaches.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Song, Chen, Liu, Chen, Wang, Wu and Liang.

Use and reproduction: